Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Novartis
Novartis
University Medicine Greifswald
Huazhong University of Science and Technology
National Cancer Institute (NCI)
Stanford University
INSYS Therapeutics Inc
National Cancer Institute (NCI)